Atopic Dermatitis

Vivacare has introduced in-depth eczema education resources from the Allergy & Asthma Network. The program will provide helpful resources for more than 3,000 allergists, dermatologists and primary car...

By week 16, most patients with moderate to severe atopic dermatitis taking upadacitinib either had a 90 percent disease clearance, or even 100 percent disease clearance.

Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet.

Pat...

The regimen was well tolerated and no serious product-related adverse events were observed. 

Daily Avena Sativa (Oat) skincare regimen provides a significant improvement in xerosis and pruritus for adult patients undergoing systemic oncology treatments,according to research presented at the A...

Arena Pharmaceuticals expects to advance etrasimod into a Phase 3 program.

Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Acad...